TGA says product information for some diabetes and weight loss drugs updated with warning of NAION disorder
-
Get our breaking news email, free app or daily news podcast
Australia’s medicines regulator has issued warnings for several type 2 diabetes and obesity-related treatments – including Ozempic and Mounjaro – over the potential to cause a “rare but severe” eye disorder that could lead to blindness.
The Therapeutic Goods Administration’s (TGA) warning came after several GLP-1 RA medicines, marketed in Australia as Ozempic, Wegovy and Mounjaro among other products, have been linked to 36 cases of the condition.
Source: The Guardian World — This article was automatically imported from the source. Read full article at original source →
